医学
多发性骨髓瘤
单克隆抗体
达拉图穆马
内科学
血液学
抗体-药物偶联物
双特异性抗体
硼替佐米
肿瘤科
来那度胺
等离子体电池
自体干细胞移植
抗体
伊扎莫布
沙利度胺
不确定意义的单克隆抗体病
临床试验
癌症研究
疾病
梅尔法兰
化疗
免疫学
单克隆
作者
Hitomi Hosoya,Surbhi Sidana
标识
DOI:10.1007/s11899-021-00624-6
摘要
The field of multiple myeloma treatment has entered a new era with antibody-based approaches in clinical practice. In this review, we focus on the clinical approaches of utilizing antibody-based modality, specifically monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell antibodies in the treatment of multiple myeloma.Three monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment of multiple myeloma. There are many ongoing clinical trials using novel targets and constructs, including bispecific antibodies against BCMA, GPRC5D, and FCRH5. In addition to exploring efficacy, there are ongoing efforts to overcome the resistance to therapy. Antibody-based therapy has improved the outcomes of patients with multiple myeloma and has been incorporated in the standard of care. We expect to see novel targets and constructs that can achieve a deeper and more durable response while minimizing toxicity, as well as better strategies for toxicity management for existing agents. We also expect that antibody-based strategies will be used in earlier lines of therapy in the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI